Browse by Medical Category
Back to Radiochemistry Program
Lee Collier, PhD
B.Sc. (Hons; 1982) and Ph.D. (1989) in Chemistry, Carleton University, Canada; Positions include: Faculty appointment at Columbia University; Senior Scientist (2003-2008) Siemens Molecular Imaging Biomarker Research. Senior Scientist, 2009–Present, Advion Inc. Research Interests: 11C and 18F radiotracer synthesis with microfluidic flow chemistry.To see a list of selected publications, visit Lee's profile on Harvard Catalyst
Microfluidic reactions in radiochemistry: This interest started during my time at CTI, Inc and resulted in a number of patent applications, and subsequently lead to my joining Advion Inc, where I have expanded on the use of microfluidics in both cold and radiotracer synthesis and purification, using the Advion NanoTek microfluidic platform. This research also includes the interfacing of microfluidic devices to other flow chemistry systems including the flow hydrogenation system by ThalesNano.
Positron and Single Photon Radiotracer synthesis: A significant component of my research occurred within the Australian Nuclear Science and Technology Organisation (Menai, Australia), Columbia University (New York, NY) and Siemens Molecular Imaging (North Wales, PA), where I expanded on the elements of rapid PET and SPECT radiosynthesis. This research resulted in the submission of four patent applications for the use of microfluidics in PET radiosynthesis.
Regulatory Affairs: I served as the chairman of the Drug Master File subcommittee for over four years and I was a member of this sub-committee at Columbia University for about 10 years. This sub-committee reviewed all chemistry, manufacturing, controls and documentation prior to submission of Investigational New Drug applications to the FDA. I have also prepared five drug master files for the preparation of PET radiotracers for human research studies at Columbia University and assisted in the preparation of eINDs and INDs for Siemens Molecular Imaging. I was also a member of the Radioactive Drug Research Committee and the Joint Radiation Safety Committee at Columbia University for about 10 years, which reviewed and approved all research involving humans and radioactivity.
Automation: Designed and constructed automated and semi-automated systems for the rapid and reliable synthesis of radiotracers and automation of the analysis of metabolites for research and human trials
Back to Top